ArticlePDF Available

Paclitaxel-induced acute fibrinous and organizing pneumonitis in early breast cancer: A case report

Authors:

Abstract and Figures

Background Paclitaxel is a chemotherapeutic drug widely used in breast cancer treatment. While common side effects are possible, paclitaxel-induced pneumonitis is rare, with an estimated incidence of 1%–5% and a high mortality rate. Case presentation A 57-year-old Thai woman diagnosed with stage II right breast cancer. She received adjuvant chemotherapy comprising doxorubicin and cyclophosphamide, followed by weekly paclitaxel. After the ninth paclitaxel cycle, she developed acute respiratory failure. Transbronchial biopsies revealed acute fibrinous and organizing pneumonitis. The patient was placed in prone position. Following the administration of dexamethasone, her symptoms improved. However, while reducing the dexamethasone dosage, she developed new-onset dyspnea as well as Takotsubo cardiomyopathy. Intravenous methylprednisolone 500 mg/day was administered for 3 days followed by transition to intravenous dexamethasone and slow tapering to prednisolone. Prednisolone was gradually tapered and eventually discontinued after 3 months. Conclusions Paclitaxel-induced pneumonitis is a rare complication. The diagnosis should be considered in any patient who develops respiratory symptoms while receiving paclitaxel. Acute fibrinous and organizing pneumonitis is a rare type of interstitial pneumonitis with high recurrence and mortality rates. High-dose steroids are needed to treat this type of pneumonitis.
Content may be subject to copyright.
Respiratory Medicine Case Reports 48 (2024) 102004
Available online 7 March 2024
2213-0071/© 2024 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contents lists available at ScienceDirect
Respiratory Medicine Case Reports
journal homepage: www.elsevier.com/locate/rmcr
Case Report
Paclitaxel-induced acute fibrinous and organizing pneumonitis in
early breast cancer: A case report
Piyarat Limpawittayakul a,*, Supinda Petchjorm b, Worawong Chueansuwan c,
Wanvisa Boonfueang d
aDivision of Medical Oncology, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand
bDivision of Pathology, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand
cDivision of Infectious Diseases, Phramongkutklao Hospital, Bangkok, Thailand
dDivision of Pulmonary Medicine, Ramkhamhaeng Hospital, Bangkok, Thailand
ARTICLE INFO
Handling Editor: DR AC Amit Chopra
Keywords:
Paclitaxel
Pneumonitis
Interstitial lung disease
ABSTRACT
Background: Paclitaxel is a chemotherapeutic drug widely used in breast cancer treatment. While
common side effects are possible, paclitaxel-induced pneumonitis is rare, with an estimated inci-
dence of 1%5% and a high mortality rate.
Case presentation: A 57-year-old Thai woman diagnosed with stage II right breast cancer. She re-
ceived adjuvant chemotherapy comprising doxorubicin and cyclophosphamide, followed by
weekly paclitaxel. After the ninth paclitaxel cycle, she developed acute respiratory failure.
Transbronchial biopsies revealed acute fibrinous and organizing pneumonitis. The patient was
placed in prone position. Following the administration of dexamethasone, her symptoms im-
proved. However, while reducing the dexamethasone dosage, she developed new-onset dyspnea
as well as Takotsubo cardiomyopathy. Intravenous methylprednisolone 500 mg/day was admin-
istered for 3 days followed by transition to intravenous dexamethasone and slow tapering to
prednisolone. Prednisolone was gradually tapered and eventually discontinued after 3 months.
Conclusions: Paclitaxel-induced pneumonitis is a rare complication. The diagnosis should be
considered in any patient who develops respiratory symptoms while receiving paclitaxel. Acute
fibrinous and organizing pneumonitis is a rare type of interstitial pneumonitis with high recur-
rence and mortality rates. High-dose steroids are needed to treat this type of pneumonitis.
1. Background
Paclitaxel, a chemotherapeutic agent originally derived from the bark of the North American yew tree, Taxus brevifolia, has been
used primarily in ovarian and breast cancer treatment [1]. Notably, paclitaxel has demonstrated significant activity in various other
cancers, including small-cell and non-small-cell lung cancer, head and neck cancers, and gastric cancer [1]. The cellular mechanism of
paclitaxel involves inducing mitotic block by stabilizing microtubules, thereby reducing the dynamic nature of these cytoskeletal
structures [2].
Common adverse effects of paclitaxel comprise neutropenia, alopecia, peripheral neuropathy, nausea with vomiting, arthralgia,
myalgia, and hypersensitivity reactions [3,4]. The latter is triggered by its diluent, polyoxyethylated castor oil, known as Cremophor
EL, and the adverse effects can be mitigated through premedication with steroids and histamine receptor antagonists [3,4]. While
common side effects are well-known, paclitaxel-induced pneumonitis is rare, cautiously estimated to occur at a rate of 1%5% [5].
* Corresponding author.
E-mail address: piyarat.lim@cra.ac.th (P. Limpawittayakul).
https://doi.org/10.1016/j.rmcr.2024.102004
Received 7 October 2023; Accepted 6 March 2024
Respiratory Medicine Case Reports 48 (2024) 102004
2
P. Limpawittayakul et al.
To the best of our knowledge, our case is the first reported instance of paclitaxel-induced acute fibrinous and organizing pneu-
monitis (AFOP). In this report, we describe the patient's clinical symptoms, radiographic and computed tomography (CT) findings,
and biopsy-confirmed AFOP resulting from paclitaxel administration. This unique case demonstrates the complexity of treatment in
drug-induced AFOP, as the symptoms temporarily improved upon steroid administration but deteriorated again upon tapering. The
patient provided informed consent.
2. Case presentation
A 57-year-old Thai woman was diagnosed with early-stage right breast cancer in February 2021. Her medical history included hy-
pertension, and she was a non-smoker. On May 3, 2021, she underwent right total mastectomy with sentinel lymph node dissection.
Pathology results revealed grade III invasive ductal carcinoma, with the mass measuring 3.1 cm in diameter. Immunohistochemical
analysis indicated negative expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2,
with a Ki67 index of 50%. Sentinel lymph node dissection showed no metastasis in the four dissected lymph nodes. This resulted in a
final pathologic stage of pT2N0M0, classified as stage II.
Following the surgery, the patient underwent four cycles of adjuvant chemotherapy with doxorubicin and cyclophosphamide, ad-
ministered at 3-week intervals. Subsequently, a regimen of weekly paclitaxel at 80 mg/m2over 1 hour was planned for 12 cycles. A
standard premedication protocol comprising dexamethasone, chlorpheniramine, and ondansetron was administered prior to the pa-
clitaxel infusion, followed by a 3-day course of dexamethasone at 8 mg per day post-infusion. The patient completed nine cycles of
weekly paclitaxel, which was generally well-tolerated, except for the development of grade II peripheral neuropathy after the fourth
cycle.
Approximately 1 week after completing the ninth cycle, the patient experienced exertional dyspnea that persisted for 2 weeks with
no cough or fever. Her symptoms worsened progressively, prompting her referral to the emergency room on the day scheduled for her
tenth cycle of paclitaxel. At this point, her oxygen saturation was 75%82% on room air, necessitating intubation. Physical examina-
tion revealed rhonchi in the right lung. A complete blood count revealed a white blood cell count of 4.7 × 10³/mL, with 85% neu-
trophils and no peripheral eosinophilia.
3. CT, computed tomography
A chest radiograph revealed multifocal reticulonodular patchy opacities in both lungs (Fig. 1A). Chest CT demonstrated newly de-
veloped multifocal consolidations and ground glass opacities in both lungs. Lesions were distributed along the peribronchovascular
regions, suggesting an infectious or inflammatory process. Additionally, several subcentimeter right paratracheal, paraaortic, subcari-
nal, and bilateral hilar lymph nodes were visible, with diameters measuring up to 0.9 cm. These were considered reactive lymph
nodes. Furthermore, concentric intraluminal filling defects were observed in the anterior, medial, and posterior basal segmental
branches of the right lower lobar pulmonary arteries, as well as the posterior basal segmental branch of the left lower lobar pul-
monary artery, indicative of acute pulmonary embolism (Fig. 1B).
Empirical antibiotic therapy comprising meropenem, levofloxacin, oseltamivir, and trimethoprim-sulfamethoxazole was initiated
to address potential bacterial/viral pneumonias and Pneumocystis carinii pneumonia. Enoxaparin treatment was also initiated for the
acute pulmonary embolism. The patient was placed on a ventilator with the fraction of inspired oxygen set at 1.0. Arterial blood gas
analysis indicated a pH of 7.319, partial pressure of carbon dioxide of 36, partial pressure of oxygen of 60.6, and an arterial pO2(P)
from arterial blood gas divided by FIO2(F) or P/F Ratio was 60.6.
Throughout her hospital stay, the patient remained afebrile, and the scant sputum was clear in color. To ascertain the cause of the
pneumonitis, bronchoscopy with bronchoalveolar lavage and transbronchial biopsies were performed the following day. Notably, the
results of throat swab real-time polymerase chain reaction (RT-PCR) testing for a panel of 33 viruses, including influenza and severe
acute respiratory syndrome coronavirus 2, were negative. Microscopic examination of the bronchoalveolar lavage using Wright's,
acid-fast bacilli, and modified acid-fast bacilli stains revealed no identifiable pathogens. Additionally, aerobic bacterial and fungal
cultures from the lavage were negative. Further testing, namely PCR for mycobacteria and Aspergillus (galactomannan) antigen, with
Fig. 1. A: Chest X-ray showing multifocal reticulonodular patchy opacities in both lungs. B: Chest CT chest showing newly developed multifocal consolidations and
ground glass opacities involving both lungs, with a peribronchovascular distribution.
Respiratory Medicine Case Reports 48 (2024) 102004
3
P. Limpawittayakul et al.
an immunofluorescence assay and PCR for Pneumocystis, yielded negative results. Hemoculture results were also negative for all speci-
mens.
Transbronchial biopsies revealed alveolar septal thickening, which was attributed to increased fibroblastic stroma and mononu-
clear inflammatory cells. Notably, frequent interalveolar fibrin leakage was observed, with a varying admixture primarily composed
of macrophages, a smaller number of lymphocytes, and occasional neutrophils. Pneumocyte hyperplasia with reactive changes was
also evident. Bronchial tissue exhibited mild lymphocyte infiltration with no neutrophil infiltration. No granulomas, foamy material,
fungi, or viral inclusions were detected. These pathological observations consistently aligned with moderate subacute lung injury,
morphologically congruent with AFOP (Fig. 2).
Following the bronchoscopy, the patient's symptoms worsened, leading to a diagnosis of paclitaxel-induced pneumonitis accom-
panied by severe acute respiratory distress syndrome. To address the patient's deteriorating condition, the muscle relaxant
cisatracurium and the sedative drugs fentanyl and midazolam were administered, and she was placed in the prone position. Intra-
venous dexamethasone at a dosage of 10 mg every 12 hours was initiated, resulting in observable symptom improvement, as evi-
denced by a chest X-ray that revealed reduced lung infiltrations compared with the earlier images (Fig. 3A). However, upon reducing
the dexamethasone dosage to 8 mg every 12 hours on the 10th day of admission, the patient experienced new-onset dyspnea. A subse-
quent chest X-ray indicated progression of multifocal reticulonodular patchy infiltrations (Fig. 3B). Concomitantly, she developed
tachy-brady arrhythmia and hypotension. The concentrations of the cardiac biomarkers creatine kinase-MB, troponin-T, and N-
terminal pro-brain natriuretic peptide were elevated. Echocardiography revealed a left ventricular ejection fraction of 10%15%,
leading to a diagnosis of Takotsubo cardiomyopathy (stress-induced cardiomyopathy). High-dose inotropic drugs, specifically norepi-
nephrine, were introduced to stabilize the hemodynamics. The patient also received a temporary pacemaker to manage the arrhyth-
mia. Intravenous methylprednisolone 500 mg was administered for 3 days, followed by transition to intravenous dexamethasone.
Fig. 2. A and Bshow the range of alveolar septal thickening from mild to moderate due to increased fibroblastic stroma (red arrow) and mononuclear inflamma-
tory cell infiltration. Cshows multiple areas of intra-alveolar fibrin leakage with mononuclear infiltration (blue arrows) and pneumocyte type II hyperplasia with
reactive atypia (red arrows). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Fig. 3. A: Chest X-ray after dexamethasone administration showing some improvement in the infiltrations. B: Chest X-ray after tapering the dose of dexametha-
sone showing increased infiltration in both lungs. C: Chest X-ray after slowly tapering the dexamethasone and eventually stopping prednisolone for 4 months
showing near-normal findings.
Respiratory Medicine Case Reports 48 (2024) 102004
4
P. Limpawittayakul et al.
Dexamethasone was continued for 30 days, after which dexamethasone was changed to prednisolone. A tracheostomy was performed
owing to the prolonged need for intubation. After 41 days of admission, the patient was successfully weaned from the ventilator.
Considering the severity of the adverse effects, the decision was made to discontinue the paclitaxel. Upon discharge, the patient re-
ceived prednisolone 0.5 mg/kg/day. Subsequent chest X-ray showed improvement in the previous findings. Follow-up echocardiogra-
phy before discharge demonstrated an improved left ventricular ejection fraction of 60%. Prednisolone was gradually tapered and
eventually discontinued 3 months after discharge. Initially requiring oxygen supplementation at home for 2 months, the patient even-
tually regained the ability to ambulate without the need for supplemental oxygen. A chest X-ray obtained 4 months after discontinu-
ing prednisolone revealed near-normal lung findings (Fig. 3C).
4. Discussion
Paclitaxel-induced pneumonitis represents a rare yet potentially fatal complication, underscoring the importance of prompt recog-
nition and management. Any patient undergoing paclitaxel treatment who presents with dyspnea and/or fever warrants considera-
tion for this complication, and early investigation through chest imaging is paramount.
The proposed risk factors for paclitaxel-induced pneumonitis are pre-existing pulmonary fibrosis, prior emphysematous changes,
concurrent radiation therapy, and combination therapy with other chemotherapy agents [6,7]. Intriguingly, factors such as smoking
status, age, and performance status have not demonstrated significant associations with the risk of pneumonitis [6,7]. Notably, the
risk of pneumonitis with paclitaxel appears to be linked to dosing schedules rather than the total dose administered. The CALGB 9840
randomized phase III trial comparing weekly and every-3-weeks paclitaxel for metastatic breast cancer revealed that the weekly
schedule resulted in a higher occurrence of grade 3 dyspnea during therapy (7% for weekly vs. 4% for every 3 weeks) [8].
Anoop et al. performed a prospective study in India and reported that among patients who received weekly paclitaxel, 10% devel-
oped acute interstitial pneumonitis after one cycle, 5% after two cycles, 3% after three cycles, 8% after five cycles, 3% after seven cy-
cles, 3% after eight cycles, and 3% after twelve cycles [9]. The median number of cycles required to induce interstitial lung disease
was five [9].
The precise mechanism underlying paclitaxel-induced pneumonitis remains incompletely understood. Two hypotheses have been
postulated: an allergic type (type I hypersensitivity reaction) and a cell-mediated cytotoxic type (type IV hypersensitivity reaction).
Type I hypersensitivity reactions involve immunoglobulin E-mediated immune responses and histamine or vasoactive substance re-
lease from basophils and mast cells. This hypersensitivity reaction is characterized by acute dyspnea, bronchospasm, hypotension,
and an erythematous rash (typically developing shortly after drug administration). This type is observed in up to 30% of cases of pa-
clitaxel-associated adverse reactions, and the rate decreases to 1%3% with steroid premedication. In contrast, type IV hypersensitiv-
ity reactions, also known as delayed-type hypersensitivity, result from T-cell-mediated reactions. Cytokine release activates T-cells or
macrophages, leading to tissue damage. Typically, this type manifests as an acute-subacute clinical course over a few hours to 2 weeks
and is characterized by bilateral pulmonary infiltrates, resembling the presentation in our case [10,11].
Notably, our case lacked peripheral eosinophilia. Peripheral eosinophilia or neutrophilia is not commonly noted, the presence of
hypereosinophilia may indicate a favorable prognosis [12].
The characteristic features observed in our case's chest CT images mirrored those of similar cases, featuring diffuse ground-glass
opacities, reticular opacities, thickened septal lines, and irregular airspace consolidations. The findings from the transbronchial
biopsy, which revealed interstitial pneumonitis predominantly infiltrated by mononuclear inflammatory cells, lend further support to
the proposed hypothesis of a type IV hypersensitivity reaction as the mechanism behind the paclitaxel-induced pneumonitis in our pa-
tient.
Of particular interest, the pathological pattern indicated AFOP, which is an infrequent histological presentation of interstitial
pneumonitis characterized by intra-alveolar fibrin deposits and widespread organizing pneumonia within alveolar ducts and bronchi-
oles. While this pattern was initially described by Travis in 2002, its etiological spectrum includes connective tissue disorders, drug
reactions, occupational exposures, and infections [13,14]. Clinically, this type of interstitial lung disease presents in two patterns: an
acute and fulminant course with rapid progression to respiratory failure and death, or a subacute, less fulminating course with even-
tual recovery. The prognosis is generally grim, marked by a high mortality rate ranging between 50% and 60% [15]. A retrospective
study from Japan by Onishi et al. found that AFOP has a high recurrence rate following steroid treatment, ranging between 60% and
76% and necessitating higher corticosteroid doses during recurrences compared with the first episode [16,17].
Diagnosing paclitaxel-induced pneumonitis entails combining clinical and radiological patterns and exposure history, and exclud-
ing other causes of diffuse pulmonary infiltration. In our case, the presence of typical clinical, radiological, and pathological findings
with the absence of evidence for other infectious agents, led to the diagnosis of paclitaxel-induced pneumonitis.
Corticosteroids remain the cornerstone of paclitaxel-induced pneumonitis treatment. In our case, prompt initiation of dexametha-
sone led to brief symptom improvement. However, attempting to reduce the steroid dose triggered symptom progression and exacer-
bation. A similar case has been reported wherein lung oxygenation improved temporarily upon steroid administration but deterio-
rated again upon tapering [4]. Given the histopathological confirmation of AFOP in our case, and the associated high recurrence rate,
we transitioned the patient to pulse methylprednisolone, administering 500 mg/day for 3 days after symptoms worsened. Recommen-
dations for grade 4 (very severe, life-threatening, or disabling) drug-induced interstitial pneumonitis advise pulse methylpred-
nisolone, followed by high-dose steroids (prednisolone 12 mg/kg/day) for 24 weeks with gradual tapering thereafter [18]. The
severity of pulmonary injury dictates the duration of corticosteroid therapy, with our case necessitating a total course of approxi-
mately 5 months.
Respiratory Medicine Case Reports 48 (2024) 102004
5
P. Limpawittayakul et al.
5. Conclusions
Paclitaxel-induced pneumonitis remains a rare complication of paclitaxel therapy.
Any patient receiving paclitaxel therapy who exhibits respiratory symptoms accompanied by a diffuse bilateral interstitial
pattern should be aware of paclitaxel-induced pneumonitis.
Prompt administration of steroids is essential upon diagnosis. Since AFOP represents an uncommon subtype of interstitial
pneumonitis with high recurrence and mortality rates, high-dose steroids are imperative to effectively manage this variant of
pneumonitis.
Ethics approval and consent to participate
This study was meticulously conducted with strict adherence to the ethical principles outlined in the Declaration of Helsinki
guidelines governing research involving human subjects. The study protocol underwent thorough review and received approval from
the Ethics Committee for Human Research at the Chulabhorn Research Institute (Certificate No.085/2566). Informed consent was
provided by the patient.
Funding
We are pleased to acknowledge the support extended by the Chulabhorn Royal Academy, Thailand, which provided funding for
the completion of this study.
Authorscontributions
Data curation, Conceptualization, original draft; and Writing - review & editing, P.L. (Piyarat Limpawittayakul); Supervision, S.P.;
Supervision, W.C. and W.B. All authors have read and agreed to the published version of the manuscript.
Declaration of competing interest
The authors hereby declare that they have no known competing financial interests or personal relationships that could potentially
influence the work presented in this manuscript.
Acknowledgements
We extend our heartfelt gratitude to the patient and her family for their invaluable participation in this research endeavor. We
would also like to acknowledge the editing assistance provided by Jane Charbonneau, DVM, from Edanz (www.edanz.com/ac) in re-
fining the draft of this manuscript.
List of abbreviations
CT Computed tomography
RT-PCR Real-time polymerase chain reaction
AFOP Acute fibrinous and organizing pneumonitis
References
[1] R. Foa, L. Norton, A.D. Seidman, Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity, Int. J. Clin. Lab. Res. 24 (1994)
614 https://doi.org/10.1007/BF02592403, PMID: 7910054.
[2] M.A. Jordan, Mechanism of action of antitumor drugs that interact with microtubules and tubulin, Curr Med Chem Anticancer Agents 2 (2002) 17https://
doi.org/10.2174/1568011023354290, PMID: 12678749.
[3] A. Khan, D. McNally, P.J. Tutschka, S. Bilgrami, Paclitaxel-induced acute bilateral pneumonitis, Ann. Pharmacother. 31 (1997) 14711474 https://doi.org/
10.1177/106002809703101205, PMID: 9416383.
[4] G.S. Wang, K.Y. Yang, R.P. Perng, Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere), Br. J. Cancer 85 (2001) 12471250 https://
doi.org/10.1054/bjoc.2001.2071, PMID: 11720456; PMCID: PMC2375237.
[5] B. Vahid, P.E. Marik, Pulmonary complications of novel antineoplastic agents for solid tumors, Chest 133 (2008) 528538 https://doi.org/10.1378/chest.07-
0851, PMID: 18252919.
[6] K. Long, K. Suresh, Pulmonary toxicity of systemic lung cancer therapy, Respirology 25 (2020) 7279 https://doi.org/10.1111/resp.13915, Epub 2020 Jul 29.
PMID: 32729207.
[7] A. Tamiya, T. Naito, S. Miura, S. Morii, A. Tsuya, Y. Nakamura, et al., Interstitial lung disease associated with docetaxel in patients with advanced non-small cell
lung cancer, Anticancer Res. 32 (2012) 11031106 PMID: 22399640.
[8] A.D. Seidman, D. Berry, C. Cirrincione, L. Harris, H. Muss, P.K. Marcom, et al., Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for
metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results
of Cancer and Leukemia Group B protocol 9840, J. Clin. Oncol. 26 (2008) 16421649 https://doi.org/10.1200/JCO.2007.11.6699, PMID: 18375893.
[9] T.M. Anoop, R. Joseph, P. Unnikrishnan, F. Thomas, M. Venugopal, Taxane-induced acute interstitial pneumonitis in patients with breast cancer and outcome of
taxane rechallenge, Lung India 39 (2022) 158 https://doi.org/10.4103/lungindia.lungindia_126_21, PMID: 35259799; PMCID: PMC9053915.
[10] S. Nagata, Y. Maehara, N. Ueda, Y. Yoshida, H. Matsuda, Severe interstitial pneumonitis associated with the administration of taxanes, J. Infect. Chemother. 16
(2010) 340344 https://doi.org/10.1007/s10156-010-0058-4, Epub 2010 Mar 31. PMID: 20354889.
[11] M. Abbas, M. Moussa, H. Akel, Type I hypersensitivity reaction, 2023 Jan, in: StatPearls [Internet], StatPearls Publishing, Treasure Island (FL, 2022 Jul 18 PMID:
32809396.
[12] L. Ardolino, B. Lau, I. Wilson, J. Chen, L. Borella, E. Stone, et al., Case report: paclitaxel-Induced pneumonitis in early breast cancer: a single institution
experience and review, Front. Oncol. 11 (2021), 701424 https://doi.org/10.3389/fonc.2021.701424, PMID: 34249762; PMCID: PMC8261280.
[13] M.B. Beasley, T.J. Franks, J.R. Galvin, B. Gochuico, W.D. Travis, Acute fibrinous and organizing pneumonia: a histologic pattern of lung injury and possible
Respiratory Medicine Case Reports 48 (2024) 102004
6
P. Limpawittayakul et al.
variant of diffuse alveolar damage, Arch. Pathol. Lab Med. 126 (2002) 10641070 https://doi.org/10.5858/2002-126-1064-AFAOP, PMID: 12204055.
[14] M.B. Beasley, T.J. Franks, J.R. Galvin, B. Gochuico, W.D. Travis, Acute fibrinous and organizing pneumonia: a histological pattern of lung injury and possible
variant of diffuse alveolar damage, Arch. Pathol. Lab Med. 126 (9) (2002 Sep) 10641070 https://doi.org/10.5858/2002-126-1064-AFAOP, PMID: 12204055.
[15] J.Y. Kim, K.W. Doo, H.J. Jang, Acute fibrinous and organizing pneumonia: imaging features, pathologic correlation, and brief literature review, Radiol Case Rep
13 (2018) 867870 https://doi.org/10.1016/j.radcr.2018.04.028, PMID: 30174771; PMCID: PMC6116343.
[16] Y. Onishi, T. Kawamura, T. Higashino, R. Mimura, H. Tsukamoto, S. Sasaki, Clinical features of acute fibrinous and organizing pneumonia: an early histologic
pattern of various acute inflammatory lung diseases, PLoS One 16 (2021), e0249300 https://doi.org/10.1371/journal.pone.0249300, PMID: 33793625; PMCID:
PMC8016294.
[17] M. Nishino, S.K. Mathai, D. Schoenfeld, S.R. Digumarthy, R.L. Kradin, Clinicopathologic features associated with relapse in cryptogenic organizing pneumonia,
Hum. Pathol. 45 (2014) 342351 https://doi.org/10.1016/j.humpath.2013.09.010, Epub 2013 Oct 3. PMID: 24342432.
[18] P. Conte, P.A. Ascierto, G. Patelli, R. Danesi, A. Vanzulli, F. Sandomenico, et al., Drug-induced interstitial lung disease during cancer therapies: expert opinion on
diagnosis and treatment, ESMO Open 7 (2022), 100404 https://doi.org/10.1016/j.esmoop.2022.100404, Epub 2022 Feb 24. PMID: 35219244; PMCID:
PMC8881716.
... Systemic chemotherapy with anthracyclines and taxanes is the most common first-line treatment modality [3]. However, anticancer drug resistance, off-target toxicity, and complications, including pneumonia with severe inflammation, are major obstacles to the development of cancer chemotherapy regimens [4][5][6]. Although the possible molecular mechanisms of TNBC tumor growth, metastasis, and therapy have been increasingly revealed, their clinical application is still limited. ...
Article
Full-text available
Background The Golgi apparatus is widely considered a secretory center and a hub for different signaling pathways. Abnormalities in Golgi dynamics can perturb the tumor microenvironment and influence cell migration. Therefore, unraveling the regulatory network of the Golgi and searching for pharmacological targets would facilitate the development of novel anticancer therapies. Previously, we reported an unconventional role for the Golgi tethering factor golgin-97 in inhibiting breast cell motility, and its downregulation was associated with poor patient prognosis. However, the specific role and regulatory mechanism of golgin-97 in cancer progression in vivo remain unclear. Methods We integrated genetic knockout (KO) of golgin-97, animal models (zebrafish and xenograft mice), multi-omics analysis (next-generation sequencing and proteomics), bioinformatics analysis, and kinase inhibitor treatment to evaluate the effects of golgin-97 KO in triple-negative breast cancer cells. Gene knockdown and kinase inhibitor treatment followed by qRT‒PCR, Western blotting, cell viability, migration, and cytotoxicity assays were performed to elucidate the mechanisms of golgin-97 KO-mediated cancer invasion. A xenograft mouse model was used to investigate cancer progression and drug therapy. Results We demonstrated that golgin-97 KO promoted breast cell metastasis in zebrafish and xenograft mouse models. Multi-omics analysis revealed that the Wnt signaling pathway, MAPK kinase cascades, and inflammatory cytokines are involved in golgin-97 KO-induced breast cancer progression. Targeting the ERK1/2 and p38 MAPK pathways effectively attenuated golgin-97-induced cancer cell migration, reduced the expression of inflammatory mediators, and enhanced the chemotherapeutic effect of paclitaxel in vitro and in vivo. Specifically, compared with the paclitaxel regimen, the combination of ERK1/2 and p38 MAPK inhibitors significantly prevented lung metastasis and lung injury. We further demonstrated that hypoxia is a physiological condition that reduces golgin-97 expression in cancer, revealing a novel and potential feedback loop between ERK/MAPK signaling and golgin-97. Conclusion Our results collectively support a novel regulatory role of golgin-97 in ERK/MAPK signaling and the tumor microenvironment, possibly providing new insights for anti-breast cancer drug development. Supplementary Information The online version contains supplementary material available at 10.1186/s12964-024-02010-0.
Article
Full-text available
Background: Although rare, taxane-induced interstitial pneumonitis is a well-recognized toxicity following chemotherapy. Data on taxane rechallenge in patients who developed taxane-induced interstitial pneumonitis following chemotherapy are limited. Here, we share our experience of acute interstitial pneumonitis following taxane chemotherapy for breast cancer and its clinical outcome following steroids and subsequent rechallenge with taxanes in selected patients without residual lung abnormalities on imaging following steroid treatment. Objectives: To study the taxane-induced acute interstitial pneumonitis in patients with breast cancer receiving chemotherapy and outcome of taxane rechallenge in these patients. Materials and methods: Patients with breast cancer who developed taxane-induced acute interstitial pneumonitis following chemotherapy either with paclitaxel or docetaxel were included. Results: Among 1240 patients with breast cancer, who received chemotherapy with either docetaxel or paclitaxel, 41 patients developed taxane-induced acute interstitial lung disease (ILD) during the study period. The interstitial pneumonitis was more seen with docetaxel. Among paclitaxel regimens, weekly schedules showed more cases of ILD than 2 weekly paclitaxel. After steroid pulse/maintenance treatment, complete resolution of lung abnormalities was seen in 76%, but residual interstitial pattern on imaging was noted in 24% of patients. Taxane rechallenge was done in 20 (49%) patients. Agents used were paclitaxel, nab-paclitaxel, or docetaxel. All rechallenged patients received short-course oral steroids for one week following taxane rechallenge as a safety measure. Rechallenge was not done in 51% either due to patient unwillingness for rechallenge (27%) or patient with residual interstitial pattern on imaging (24%). None of the patients experienced any recurrence of pneumonitis or any mortality following taxane rechallenge. Conclusion: Acute interstitial pneumonitis is a well-known toxicity following taxanes in breast cancer and taxane rechallenge is an option in those patients without any residual pneumonitis following steroid pulse/maintenance. We also advise short-course oral steroids for 1 week following taxane rechallenge as a safety measure. We strongly do not recommend rechallenge in patients with residual lung abnormalities after steroids.
Article
Full-text available
Background Drug-induced interstitial lung disease (DIILD) is a form of interstitial lung disease resulting from exposure to drugs causing inflammation and possibly interstitial fibrosis. Antineoplastic drugs are the primary cause of DIILD, accounting for 23%-51% of cases, with bleomycin, everolimus, erlotinib, trastuzumab-deruxtecan and immune checkpoint inhibitors being the most common causative agents. DIILD can be difficult to identify and manage, and there are currently no specific guidelines on the diagnosis and treatment of DIILD caused by anticancer drugs. Objective To develop recommendations for the diagnosis and management of DIILD in cancer patients. Methods Based on the published literature and their clinical expertise, a multidisciplinary group of experts in Italy developed recommendations stratified by DIILD severity, based on the Common Terminology Criteria for Adverse Events. Results The recommendations highlight the importance of multidisciplinary interaction in the diagnosis and management of DIILD. Important components of the diagnostic process are physical examination and careful patient history-taking, measurement of vital signs (particularly respiratory rate and arterial oxygen saturation), relevant laboratory tests, respiratory function testing with spirometry and diffusing capacity of the lung for carbon monoxide and computed tomography/imaging. Because the clinical and radiological signs of DIILD are often similar to those of pneumonias or interstitial lung diseases, differential diagnosis is important, including microbial and serological testing to exclude or confirm infectious causes. In most cases, management of DIILD requires the discontinuation of the antineoplastic agent and the administration of short-term steroids. Steroid tapering must be undertaken slowly to prevent reactivation of DIILD. Patients with severe and very severe (grade 3 and 4) DIILD will require hospitalisation and often need oxygen and non-invasive ventilation. Decisions about invasive ventilation should take into account the patient’s cancer prognosis. Conclusions These recommendations provide a structured step-by-step diagnostic and therapeutic approach for each grade of suspected cancer-related DIILD.
Article
Full-text available
Taxane-based chemotherapy regimens are in widespread use as standard of care treatment for patients with early breast cancer, though rarely its use can be complicated by taxane-induced pneumonitis (TIP). While breast cancer is the most diagnosed cancer in women worldwide, TIP remains under-described in this setting. Key questions relate to its incidence, diagnosis and management, potential predictive biomarkers, and the balance between this life-threatening toxicity and curatively intended treatment. At a single Australian institution, 6 cases of TIP are identified among 132 patients treated with a paclitaxel-containing regimen for early breast cancer (4.55%, 95% confidence interval 1.69-9.63%). This review first outlines the presentation, management, and outcomes for these cases, then answers these questions and proposes an approach to suspected TIP in patients with breast cancer.
Article
Full-text available
Background Acute fibrinous and organizing pneumonia (AFOP) is a rare histologic pattern of acute lung involvement with intra-alveolar fibrin deposition. However, the clinical significance of the pathological findings of AFOP remains unclear. This study aimed to explore the clinical significance of AFOP through a comprehensive clinical examination. Methods The medical records of patients with lung diseases accompanied by the pathological finding of intra-alveolar organization between January 2010 and December 2019 were retrospectively reviewed. The clinical and radiological findings were compared between the groups with and without the histologic pattern of AFOP. Results We identified 34 patients with AFOP (AFOP group) and 143 without AFOP (non-AFOP group). The underlying diseases of the AFOP group were as follows: 19 patients had cryptogenic organizing pneumonia (OP), 5 had connective tissue diseases, 3 had radiation pneumonitis, 3 had chronic eosinophilic pneumonia, 2 had myelodysplastic syndromes, and 2 had drug-induced pneumonia. Fever was more common, the time from symptom onset to biopsy was shorter, and the serum C-reactive protein level was higher in the AFOP group than in the non-AFOP group. On high-resolution computed tomography, 85% of patients had OP pattern, and halo sign was more common in the AFOP group. Corticosteroids were effective in 94% of the patients in the AFOP group; however, recurrences were more frequent, and a higher corticosteroid dose was needed during recurrence. Conclusions AFOP might be an early phase of a histologic pattern associated with known etiologies. In addition, it could be a marker indicating intense inflammatory diseases with a tendency of recurrence.
Article
Full-text available
Acute fibrinous and organizing pneumonia is a histopathologic entity of lung injury with the hallmark feature of intra-alveolar fibrin “balls.” We report 2 cases of acute fibrinous and organizing pneumonia in patients without a significant medical history, who presented with cough and worsening dyspnea and experienced a fulminant course of disease progression with diffuse lung parenchymal abnormalities on chest computed tomography. These cases suggest that this rare histologic pattern of idiopathic interstitial pneumonias can be included in the differential diagnosis with other conditions leading to acute respiratory failure.
Article
Full-text available
Docetaxel is a well tolerated chemotherapy for non-small cell lung cancer (NSCLC). However, few studies have investigated interstitial lung disease (ILD) associated with docetaxel. The purpose is to describe the incidence of this complication by using NSCLC patients. Between September 2002 and March 2008, 392 patients with advanced NSCLC were treated with docetaxel and we retrospectively reviewed the radiography. In total, 18 patients subsequently developed ILD associated with docetaxel. The incidence of ILD associated with docetaxel was 4.6%. In treated patients who showed an interstitial change on chest computed tomography (CT), the incidence was very high (25.9%). Chest radiograph showed diffuse and bilateral ground-glass appearance patterns. Pre-existing interstitial change on CT was associated with a higher incidence of ILD (25.9%) among NSCLC patients treated with docetaxel. We don't recommend administering docetaxel for the patients with pre-existing interstitial change.
Article
Lung cancer is the leading cause of cancer‐related deaths worldwide. As new therapies are developed, it is important to understand the pulmonary toxicities associated with systemic lung cancer therapies. Cytotoxic chemotherapy regimens for NSCLC often include taxanes. Pulmonary toxicity from taxanes presents as an ILD‐type reaction characterized by increasing dyspnoea, dry cough, fever and bilateral pulmonary interstitial infiltrates. The incidence of taxane‐induced pneumonitis is rare, and many patients respond to steroid therapy; however, fatal cases have been reported. Patients with NSCLC are routinely tested for the presence of tumour oncogenes to determine their candidacy for targeted therapies, such as TKI. EGFR‐TKI can cause pneumonitis characterized by progressive dyspnoea and hypoxia. EGFR‐TKI‐associated ILD rarely presents as an AIP with rapidly progressive respiratory failure and high mortality rates. The most recent development in lung cancer therapy has been the discovery of immune checkpoint inhibitor (ICI). ICI pneumonitis has been increasingly recognized as a common complication of ICI therapy, with reported incidence as high as 19% in some clinical settings. Early‐grade ICI pneumonitis may be asymptomatic; however, high‐grade ICI pneumonitis can result in progressive dyspnoea, hypoxia and respiratory failure. ICI pneumonitis is unique in that only half of the patients will improve with steroid treatment, and mortality rates are high. As treatment of NSCLC evolves, providers must be able to recognize and respond to the development of drug‐induced pulmonary toxicities.
Article
Organizing pneumonia (OP) is a histopathologic pattern of response to lung injury. Fibrin is a marker of acute microvascular injury, and variable amounts of intraalveolar fibrin are seen in OP; however, its relevance to clinical outcomes is unclear. We examined lung wedge biopsies of 26 patients with cryptogenic organizing pneumonia (COP), assessed the amount of fibrin associated with airspace organization, and correlated fibrin levels with other histologic, clinical, and radiographic findings. Seven patients with COP had disease relapse. Patients with multifocal fibrin deposits or acute fibrinous and organizing pneumonia (collectively, "high fibrin") showed a higher rate of OP relapse compared to those with no or focal fibrin (60% versus 6%, P < .05). Patients with radiographic evidence of disease involving all three lung zones (upper, middle, and lower) also showed higher rates of relapse compared to those in whom disease was limited to one or two zones (41% versus 0%, P = .055). In patients with both pathologic evidence of high fibrin and radiographic evidence of three-zone disease, OP relapse could be predicted with a sensitivity of 86% and specificity of 84% (positive predictive value of 67% and negative predictive value of 94%). The presence of high levels of intraalveolar fibrin in lung biopsies and radiographic evidence of disease involving all three lung zones is associated with increased risk of relapse in patients with COP, and these features may help identify patients who may benefit from more intensive steroid therapy.
Article
Interstitial pneumonitis has sporadically been reported as a toxic effect of taxanes such as docetaxel and paclitaxel. This report describes 2 patients who developed interstitial pneumonitis after receiving chemotherapy including taxanes, and both cases grew serious enough to require respiratory support. The first case was a 57-year-old man with gastric cancer treated with docetaxel biweekly and S-1 for 2 weeks as adjuvant chemotherapy. After 4 courses of docetaxel, he presented acute dyspnea. The second case was a 66-year-old woman with breast cancer and postoperative pleural recurrence treated with weekly paclitaxel as fourth-line chemotherapy. She developed a dry cough, high fever, and dyspnea after 1 course of paclitaxel. In both cases, computed tomography (CT) showed extensive bilateral areas of ground-glass attenuation. They developed progressive interstitial infiltrates and respiratory failure that required mechanical ventilation. Taxane-induced interstitial pneumonitis was diagnosed to exclude other causes. From previous reports, intubation is associated with the survival of patients with taxane-induced interstitial pneumonitis. However, corticosteroid therapy was dramatically effective and resolved the interstitial pneumonitis in both our patients. Clinicians should be aware of this occasional complication during the course of chemotherapy with taxanes and initiate treatment, including respiratory support, as soon as possible.
Article
Allergy to latex causes serious accidents that are often unrecognised. These accidents are perfectly predictable by a simple interrogation, together with skin and biological tests. Populations at risk can be identified: persons undergoing treatment, particularly the disabled and also housewives. There is a risk of further increases in the number of cases of hypersensitivity to latex due to the expanding use of preservatives. The study undertaken at the CHU at Angers has shown that allergy to fruits is frequent in patients who are sensitive to latex. The exact nature of allergy to Hevea is not yet well understood: it is not possible at present to decide whether there is "crossed allergy" or whether it is one part of a larger syndrome.